Business Wire10.12.18
Renovia Inc., a company dedicated to discovering and delivering first-line digital therapeutic and diagnostic devices for women with pelvic floor disorders, has appointed Dan Levangie to its Board of Directors.
"Dan Levangie has an outstanding track record of leading major life science companies as they scale operations and drive productivity,” said Marc Beer, co-founder, chairman and CEO of Renovia.
Currently, Levangie is the co-founder and managing partner of ATON Partners, a private investment and management consulting firm focused on early-stage medical device and diagnostic technologies. Prior to founding ATON Partners in 2013, Levangie held executive management positions at several leading medical device and investment companies, including Insulet Corporation, Cytyc Corporation, Constitution Medical Investors and Dune Medical Devices, where he served as CEO for two years.
At Cytyc, Levangie held a variety of executive management positions from 1992 until Cytyc’s acquisition by Hologic Inc. in 2007, including chief operating officer. During his tenure at Cytyc, Levangie led the launch of its ThinPrep testing system, the most widely used Pap test in the world.
"Dan brings a wealth of knowledge in the medical device, diagnostic and women’s health fields," said Marc Beer. "Dan has led multiple healthcare companies through periods of rapid clinical innovation and commercial growth. Under his leadership, Cytyc no less than revolutionized the standard of care for Pap testing. I can’t think of a better advisor to Renovia as we look to build out our portfolio of digital therapeutics and diagnostics."
Levangie resides in Boston, Mass., with his wife Joan, and is a member of the Board of Directors of Exact Sciences Inc., Dune Medical Devices and CereVasc LLC. Levangie, a graduate of the College of Pharmacy of Northeastern University in Boston, is a member of the Advisory Board of the Barnett Institute of Northeastern University and is a trustee of Excel Charter School, East Boston.
“I am so impressed by Renovia’s focus on developing transformative technologies backed by world-class clinical testing," Levangie said. "Renovia’s device technology and data-rich app interface provide precise, user-friendly treatment of weakened pelvic floor muscles enabling valuable real-time feedback, while the data captured over time also informs treatment. I am thrilled to work with the Renovia team as they continue to develop innovative approaches to diagnose and treat pelvic floor disorders.”
Renovia was formed to develop and commercialize products for better first-line diagnosis and treatment to improve the condition-specific quality of life for millions of women with pelvic floor disorders. Renovia's technology enables treatment via precise visualization of pelvic movement in real-time during pelvic floor muscle training, while monitoring usage and progress over time. As a women's health organization, Renovia is in pursuit of scalable and cost-effective care for pelvic floor disorders delivered through the power of digital health.
"Dan Levangie has an outstanding track record of leading major life science companies as they scale operations and drive productivity,” said Marc Beer, co-founder, chairman and CEO of Renovia.
Currently, Levangie is the co-founder and managing partner of ATON Partners, a private investment and management consulting firm focused on early-stage medical device and diagnostic technologies. Prior to founding ATON Partners in 2013, Levangie held executive management positions at several leading medical device and investment companies, including Insulet Corporation, Cytyc Corporation, Constitution Medical Investors and Dune Medical Devices, where he served as CEO for two years.
At Cytyc, Levangie held a variety of executive management positions from 1992 until Cytyc’s acquisition by Hologic Inc. in 2007, including chief operating officer. During his tenure at Cytyc, Levangie led the launch of its ThinPrep testing system, the most widely used Pap test in the world.
"Dan brings a wealth of knowledge in the medical device, diagnostic and women’s health fields," said Marc Beer. "Dan has led multiple healthcare companies through periods of rapid clinical innovation and commercial growth. Under his leadership, Cytyc no less than revolutionized the standard of care for Pap testing. I can’t think of a better advisor to Renovia as we look to build out our portfolio of digital therapeutics and diagnostics."
Levangie resides in Boston, Mass., with his wife Joan, and is a member of the Board of Directors of Exact Sciences Inc., Dune Medical Devices and CereVasc LLC. Levangie, a graduate of the College of Pharmacy of Northeastern University in Boston, is a member of the Advisory Board of the Barnett Institute of Northeastern University and is a trustee of Excel Charter School, East Boston.
“I am so impressed by Renovia’s focus on developing transformative technologies backed by world-class clinical testing," Levangie said. "Renovia’s device technology and data-rich app interface provide precise, user-friendly treatment of weakened pelvic floor muscles enabling valuable real-time feedback, while the data captured over time also informs treatment. I am thrilled to work with the Renovia team as they continue to develop innovative approaches to diagnose and treat pelvic floor disorders.”
Renovia was formed to develop and commercialize products for better first-line diagnosis and treatment to improve the condition-specific quality of life for millions of women with pelvic floor disorders. Renovia's technology enables treatment via precise visualization of pelvic movement in real-time during pelvic floor muscle training, while monitoring usage and progress over time. As a women's health organization, Renovia is in pursuit of scalable and cost-effective care for pelvic floor disorders delivered through the power of digital health.
